NO307027B1 - Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader - Google Patents

Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader

Info

Publication number
NO307027B1
NO307027B1 NO952230A NO952230A NO307027B1 NO 307027 B1 NO307027 B1 NO 307027B1 NO 952230 A NO952230 A NO 952230A NO 952230 A NO952230 A NO 952230A NO 307027 B1 NO307027 B1 NO 307027B1
Authority
NO
Norway
Prior art keywords
riluzole
treatment
pct
traumatic injuries
neurological lesions
Prior art date
Application number
NO952230A
Other languages
English (en)
Norwegian (no)
Other versions
NO952230L (no
NO952230D0 (no
Inventor
Adam Doble
Erik Louvel
Jeremy Pratt
Jean-Marie Stutzmann
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Publication of NO952230L publication Critical patent/NO952230L/no
Publication of NO952230D0 publication Critical patent/NO952230D0/no
Publication of NO307027B1 publication Critical patent/NO307027B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Data Exchanges In Wide-Area Networks (AREA)
NO952230A 1992-12-16 1995-06-06 Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader NO307027B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9215148A FR2699077B1 (fr) 1992-12-16 1992-12-16 Application d'anticonvulsivants dans le traitement de lésions neurologiques liées à des traumatismes.
PCT/FR1993/001229 WO1994013288A1 (fr) 1992-12-16 1993-12-10 Application du riluzole dans le traitement de lesions neurologiques liees a des traumatismes

Publications (3)

Publication Number Publication Date
NO952230L NO952230L (no) 1995-06-06
NO952230D0 NO952230D0 (no) 1995-06-06
NO307027B1 true NO307027B1 (no) 2000-01-31

Family

ID=9436652

Family Applications (3)

Application Number Title Priority Date Filing Date
NO952228A NO952228L (no) 1992-12-16 1995-06-06 Anvendelse av lamotrigin ved behandling av neurologiske lesjoner relatert til traumatiske skader
NO952230A NO307027B1 (no) 1992-12-16 1995-06-06 Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader
NO952229A NO952229L (no) 1992-12-16 1995-06-06 Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO952228A NO952228L (no) 1992-12-16 1995-06-06 Anvendelse av lamotrigin ved behandling av neurologiske lesjoner relatert til traumatiske skader

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO952229A NO952229L (no) 1992-12-16 1995-06-06 Anvendelse av karbamazepin og okskarbazepin ved behandling av neurologiske lesjoner relatert til traumatiske skader

Country Status (23)

Country Link
US (1) US5830907A (sk)
EP (3) EP0674518A1 (sk)
JP (3) JPH08504428A (sk)
KR (3) KR950703968A (sk)
AT (1) ATE164067T1 (sk)
AU (3) AU5702094A (sk)
CA (3) CA2151601A1 (sk)
CZ (3) CZ284420B6 (sk)
DE (1) DE69317578T2 (sk)
DK (1) DK0674512T3 (sk)
ES (1) ES2113635T3 (sk)
FR (1) FR2699077B1 (sk)
GR (1) GR3026403T3 (sk)
HU (3) HUT71839A (sk)
IL (3) IL108051A (sk)
MX (3) MX9307884A (sk)
NO (3) NO952228L (sk)
PL (3) PL309347A1 (sk)
RU (1) RU2142800C1 (sk)
SK (3) SK78595A3 (sk)
UA (1) UA41906C2 (sk)
WO (3) WO1994013296A1 (sk)
ZA (3) ZA939400B (sk)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
FR2733684B1 (fr) 1995-05-03 1997-05-30 Cird Galderma Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
GB9512854D0 (en) * 1995-06-23 1995-08-23 Wellcome Found Novel formulation
CO4920215A1 (es) * 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
US20020022056A1 (en) 1997-02-14 2002-02-21 Burkhard Schlutermann Oxacarbazepine film-coated tablets
ES2231757T3 (es) 1997-09-05 2005-05-16 Glaxo Group Limited Composiciones farmaceutica que comprenden derivados de 2,3-diaril-pirazolo (1,5-b) piridazina.
GB9808015D0 (en) * 1998-04-15 1998-06-17 United Medical And Dental Scho Protection of the nervous system from the effects of inflammatory disease
US6150423A (en) * 1998-10-15 2000-11-21 Phoenix Scientific, Inc. Propofol-based anesthetic and method of making same
FR2787028B1 (fr) 1998-12-15 2002-10-18 Aventis Pharma Sa Utilisation du riluzole dans le traitement des traumatismes acoustiques
US6239156B1 (en) * 1999-04-29 2001-05-29 Centre National De La Recherche Scientifique Cnrs Method for the prevention of ischemic spinal cord injury caused by aortic crossclamping
GB9925962D0 (en) * 1999-11-02 1999-12-29 Novartis Ag Organic compounds
GB9930058D0 (en) * 1999-12-20 2000-02-09 Novartis Ag Organic compounds
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
US9629817B2 (en) 2005-08-25 2017-04-25 Steven Michael Weiss Reducing myocardial damage and the incidence of arrhythmia arising from loss, reduction or interruption in coronary blood flow
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
US9399634B2 (en) 2012-05-07 2016-07-26 Cellix Bio Private Limited Compositions and methods for the treatment of depression
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9273061B2 (en) 2012-05-10 2016-03-01 Cellix Bio Private Limited Compositions and methods for the treatment of chronic pain
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013167997A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9498461B2 (en) 2012-05-23 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
EP2852569B1 (en) 2012-05-23 2020-10-14 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
US9187427B2 (en) 2012-08-03 2015-11-17 Cellix Bio Private Limited N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
EP2892878A4 (en) 2012-09-08 2016-02-24 Cellix Bio Private Ltd COMPOSITIONS AND METHODS FOR TREATING INFLAMMATION AND LIPID DISORDER
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
WO2016046835A1 (en) 2014-09-26 2016-03-31 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
CN107108535B (zh) 2014-10-27 2020-04-28 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的富马酸单甲酯与哌嗪或乙二胺的三组分盐
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
JP6679616B2 (ja) 2015-01-06 2020-04-22 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ 炎症及び疼痛の治療のための組成物及び方法
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
KR102510784B1 (ko) * 2017-03-30 2023-03-15 엑스더블유파마 리미티드 이환형 헤테로아릴 유도체 및 이의 제조 및 용도
US10322114B2 (en) 2017-07-31 2019-06-18 Above And Beyond Nb, Llc Formulation of a riluzole solution with beta-cyclodextrins
WO2019108594A1 (en) * 2017-11-28 2019-06-06 University Of Houston System Liquid formulations of riluzole for oral and intravenous use
WO2020062251A1 (en) 2018-09-30 2020-04-02 Xw Laboratories, Inc. Compounds as neuronal histamine receptor-3 antagonists and uses thereof
KR20220133189A (ko) 2019-12-20 2022-10-04 엑스더블유파마 리미티드 4-발레릴옥시부티르산의 합성 방법
WO2021257886A1 (en) 2020-06-18 2021-12-23 XWPharma Ltd. Controlled release granulations of water-soluble active pharmaceutical ingredients
WO2021257832A1 (en) 2020-06-18 2021-12-23 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
AU2021357705A1 (en) 2020-10-05 2023-05-18 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
TW202300139A (zh) 2021-03-19 2023-01-01 凱瑞康寧生技股份有限公司 γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR68380B (sk) * 1979-06-01 1981-12-28 Wellcome Found
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
US4431641A (en) * 1980-10-17 1984-02-14 Ciba-Geigy Corporation Pharmaceutical compositions having antiepileptic and antineuralgic action
GB8613183D0 (en) * 1986-05-30 1986-07-02 Wellcome Found Triazine salt
US4826860A (en) * 1987-03-16 1989-05-02 Warner-Lambert Company Substituted 2-aminobenzothiazoles and derivatives useful as cerebrovascular agents
US4918090A (en) * 1988-01-25 1990-04-17 Warner-Lambert Company Substituted 2-aminbenzothiazoles and derivatives useful as cerebrovascular agents
US5240948A (en) * 1989-12-13 1993-08-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. 3-(3-alkylthiopropyl)benzothiazoline derivatives, their preparation and the medicament containing them
GB9012312D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
JPH06506455A (ja) * 1991-02-08 1994-07-21 ケンブリッジ・ニューロサイエンス・インコーポレイテッド 神経伝達物質放出調節剤としてのグアニジン置換体及びその誘導体ならびに神経伝達物質放出遮断物質を同定するための新規な方法
FR2688138B1 (fr) * 1992-03-06 1995-05-05 Rhone Poulenc Rorer Sa Application de l'amino-2 trifluoromethoxy-6 benzothiazole pour obtenir un medicament destine au traitement de la sclerose laterale amyotrophique.

Also Published As

Publication number Publication date
AU5654094A (en) 1994-07-04
ZA939400B (en) 1994-08-19
ZA939401B (en) 1994-08-19
CZ154795A3 (en) 1995-11-15
EP0674512B1 (fr) 1998-03-18
RU2142800C1 (ru) 1999-12-20
AU5702094A (en) 1994-07-04
FR2699077B1 (fr) 1995-01-13
SK279759B6 (sk) 1999-03-12
NO952228D0 (no) 1995-06-06
HU217133B (hu) 1999-11-29
CZ154695A3 (en) 1995-11-15
CA2151603A1 (fr) 1994-06-23
CZ154595A3 (en) 1995-11-15
AU678795B2 (en) 1997-06-12
ES2113635T3 (es) 1998-05-01
EP0674512A1 (fr) 1995-10-04
UA41906C2 (uk) 2001-10-15
EP0674518A1 (fr) 1995-10-04
NO952228L (no) 1995-06-06
JPH08504428A (ja) 1996-05-14
JPH08504429A (ja) 1996-05-14
AU5653994A (en) 1994-07-04
FR2699077A1 (fr) 1994-06-17
DE69317578D1 (de) 1998-04-23
NO952229D0 (no) 1995-06-06
JPH08504430A (ja) 1996-05-14
IL108051A (en) 1999-05-09
HU9501753D0 (en) 1995-08-28
PL309348A1 (en) 1995-10-02
KR950703968A (ko) 1995-11-17
CZ284420B6 (cs) 1998-11-11
SK78795A3 (en) 1996-05-08
NO952230L (no) 1995-06-06
ATE164067T1 (de) 1998-04-15
CA2151601A1 (fr) 1994-06-23
CA2151604A1 (fr) 1994-06-23
MX9307884A (es) 1994-06-30
KR950703965A (ko) 1995-11-17
IL108053A0 (en) 1994-04-12
NO952229L (no) 1995-06-06
HUT71839A (en) 1996-02-28
WO1994013288A1 (fr) 1994-06-23
MX9307882A (es) 1994-06-30
NO952230D0 (no) 1995-06-06
DE69317578T2 (de) 1998-07-23
DK0674512T3 (da) 1998-05-25
ZA939399B (en) 1994-08-22
MX9307883A (es) 1994-06-30
US5830907A (en) 1998-11-03
PL309346A1 (en) 1995-10-02
HUT71812A (en) 1996-02-28
PL309347A1 (en) 1995-10-02
HU9501751D0 (en) 1995-08-28
EP0674520A1 (fr) 1995-10-04
IL108051A0 (en) 1994-04-12
SK78595A3 (en) 1996-05-08
CA2151604C (fr) 2005-09-20
SK78695A3 (en) 1996-05-08
KR100298808B1 (ko) 2001-11-22
IL108052A0 (en) 1994-04-12
HU9501752D0 (en) 1995-08-28
KR950703954A (ko) 1995-11-17
WO1994013296A1 (fr) 1994-06-23
GR3026403T3 (en) 1998-06-30
WO1994013298A1 (fr) 1994-06-23
HUT71814A (en) 1996-02-28
JP3712239B2 (ja) 2005-11-02

Similar Documents

Publication Publication Date Title
NO307027B1 (no) Anvendelse av riluzol ved behandling av neurologiske lesjoner relatert til traumatiske skader
PL309594A1 (en) Apllication of rilusole in treating parkinson disease and parkinsonian syndromes
KR960701051A (ko) 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases)
ZA9427B (en) Use of riluzole for promoting restoration following radiation

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees